Pharma & Healthcare
Global Direct Acting Antivirals Market Research Report 2026
- Feb 24, 26
- ID: 719588
- Pages: 122
- Figures: 119
- Views: 8
This report delivers a comprehensive overview of the global Direct Acting Antivirals market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Direct Acting Antivirals. The Direct Acting Antivirals market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Direct Acting Antivirals market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Direct Acting Antivirals manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Gilead Sciences
Asegua Therapeutics
Merck
AbbVie
Bristol Myers Squibb
Ascletis Pharma
Kawin Technology
YiChang HEC ChangJiang Pharmaceutical
Sanhome Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Cosunter pharmaceutical
Beijing Sihuan Pharmaceutical
Segment by Type
Pangenotypic
Genotype-Specific
by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Direct Acting Antivirals manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Direct Acting Antivirals sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Direct Acting Antivirals market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Direct Acting Antivirals manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Gilead Sciences
Asegua Therapeutics
Merck
AbbVie
Bristol Myers Squibb
Ascletis Pharma
Kawin Technology
YiChang HEC ChangJiang Pharmaceutical
Sanhome Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Cosunter pharmaceutical
Beijing Sihuan Pharmaceutical
Segment by Type
Pangenotypic
Genotype-Specific
by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Direct Acting Antivirals manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Direct Acting Antivirals sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Direct Acting Antivirals Market Overview
1.1 Product Definition
1.2 Direct Acting Antivirals by Type
1.2.1 Global Direct Acting Antivirals Market Value by Type: 2025 vs 2032
1.2.2 Pangenotypic
1.2.3 Genotype-Specific
1.3 Direct Acting Antivirals by Application
1.3.1 Global Direct Acting Antivirals Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Direct Acting Antivirals Market Size Estimates and Forecasts
1.4.1 Global Direct Acting Antivirals Revenue 2021–2032
1.4.2 Global Direct Acting Antivirals Sales 2021–2032
1.4.3 Global Direct Acting Antivirals Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Direct Acting Antivirals Market Competition by Manufacturers
2.1 Global Direct Acting Antivirals Sales Market Share by Manufacturers (2021–2026)
2.2 Global Direct Acting Antivirals Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Direct Acting Antivirals Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Direct Acting Antivirals, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Direct Acting Antivirals, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Direct Acting Antivirals, Product Types and Applications
2.7 Global Key Manufacturers of Direct Acting Antivirals, Date of Entry into the Industry
2.8 Global Direct Acting Antivirals Market Competitive Situation and Trends
2.8.1 Global Direct Acting Antivirals Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Direct Acting Antivirals Players Market Share by Revenue
2.8.3 Global Direct Acting Antivirals Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Direct Acting Antivirals Market Scenario by Region
3.1 Global Direct Acting Antivirals Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Direct Acting Antivirals Sales by Region: 2021–2032
3.2.1 Global Direct Acting Antivirals Sales by Region: 2021–2026
3.2.2 Global Direct Acting Antivirals Sales by Region: 2027–2032
3.3 Global Direct Acting Antivirals Revenue by Region: 2021–2032
3.3.1 Global Direct Acting Antivirals Revenue by Region: 2021–2026
3.3.2 Global Direct Acting Antivirals Revenue by Region: 2027–2032
3.4 North America Direct Acting Antivirals Market Facts & Figures by Country
3.4.1 North America Direct Acting Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Direct Acting Antivirals Sales by Country (2021–2032)
3.4.3 North America Direct Acting Antivirals Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Direct Acting Antivirals Market Facts & Figures by Country
3.5.1 Europe Direct Acting Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Direct Acting Antivirals Sales by Country (2021–2032)
3.5.3 Europe Direct Acting Antivirals Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Direct Acting Antivirals Market Facts & Figures by Region
3.6.1 Asia Pacific Direct Acting Antivirals Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Direct Acting Antivirals Sales by Region (2021–2032)
3.6.3 Asia Pacific Direct Acting Antivirals Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Direct Acting Antivirals Market Facts & Figures by Country
3.7.1 Latin America Direct Acting Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Direct Acting Antivirals Sales by Country (2021–2032)
3.7.3 Latin America Direct Acting Antivirals Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Direct Acting Antivirals Market Facts & Figures by Country
3.8.1 Middle East and Africa Direct Acting Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Direct Acting Antivirals Sales by Country (2021–2032)
3.8.3 Middle East and Africa Direct Acting Antivirals Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Direct Acting Antivirals Sales by Type (2021–2032)
4.1.1 Global Direct Acting Antivirals Sales by Type (2021–2026)
4.1.2 Global Direct Acting Antivirals Sales by Type (2027–2032)
4.1.3 Global Direct Acting Antivirals Sales Market Share by Type (2021–2032)
4.2 Global Direct Acting Antivirals Revenue by Type (2021–2032)
4.2.1 Global Direct Acting Antivirals Revenue by Type (2021–2026)
4.2.2 Global Direct Acting Antivirals Revenue by Type (2027–2032)
4.2.3 Global Direct Acting Antivirals Revenue Market Share by Type (2021–2032)
4.3 Global Direct Acting Antivirals Price by Type (2021–2032)
5 Segment by Application
5.1 Global Direct Acting Antivirals Sales by Application (2021–2032)
5.1.1 Global Direct Acting Antivirals Sales by Application (2021–2026)
5.1.2 Global Direct Acting Antivirals Sales by Application (2027–2032)
5.1.3 Global Direct Acting Antivirals Sales Market Share by Application (2021–2032)
5.2 Global Direct Acting Antivirals Revenue by Application (2021–2032)
5.2.1 Global Direct Acting Antivirals Revenue by Application (2021–2026)
5.2.2 Global Direct Acting Antivirals Revenue by Application (2027–2032)
5.2.3 Global Direct Acting Antivirals Revenue Market Share by Application (2021–2032)
5.3 Global Direct Acting Antivirals Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences Direct Acting Antivirals Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 Asegua Therapeutics
6.2.1 Asegua Therapeutics Company Information
6.2.2 Asegua Therapeutics Description and Business Overview
6.2.3 Asegua Therapeutics Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Asegua Therapeutics Direct Acting Antivirals Product Portfolio
6.2.5 Asegua Therapeutics Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Merck Direct Acting Antivirals Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Company Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 AbbVie Direct Acting Antivirals Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 Bristol Myers Squibb
6.5.1 Bristol Myers Squibb Company Information
6.5.2 Bristol Myers Squibb Description and Business Overview
6.5.3 Bristol Myers Squibb Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Bristol Myers Squibb Direct Acting Antivirals Product Portfolio
6.5.5 Bristol Myers Squibb Recent Developments/Updates
6.6 Ascletis Pharma
6.6.1 Ascletis Pharma Company Information
6.6.2 Ascletis Pharma Description and Business Overview
6.6.3 Ascletis Pharma Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Ascletis Pharma Direct Acting Antivirals Product Portfolio
6.6.5 Ascletis Pharma Recent Developments/Updates
6.7 Kawin Technology
6.7.1 Kawin Technology Company Information
6.7.2 Kawin Technology Description and Business Overview
6.7.3 Kawin Technology Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Kawin Technology Direct Acting Antivirals Product Portfolio
6.7.5 Kawin Technology Recent Developments/Updates
6.8 YiChang HEC ChangJiang Pharmaceutical
6.8.1 YiChang HEC ChangJiang Pharmaceutical Company Information
6.8.2 YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
6.8.3 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio
6.8.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
6.9 Sanhome Pharmaceutical
6.9.1 Sanhome Pharmaceutical Company Information
6.9.2 Sanhome Pharmaceutical Description and Business Overview
6.9.3 Sanhome Pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio
6.9.5 Sanhome Pharmaceutical Recent Developments/Updates
6.10 Chia Tai Tianqing Pharmaceutical
6.10.1 Chia Tai Tianqing Pharmaceutical Company Information
6.10.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.10.3 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio
6.10.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.11 Cosunter pharmaceutical
6.11.1 Cosunter pharmaceutical Company Information
6.11.2 Cosunter pharmaceutical Description and Business Overview
6.11.3 Cosunter pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio
6.11.5 Cosunter pharmaceutical Recent Developments/Updates
6.12 Beijing Sihuan Pharmaceutical
6.12.1 Beijing Sihuan Pharmaceutical Company Information
6.12.2 Beijing Sihuan Pharmaceutical Description and Business Overview
6.12.3 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio
6.12.5 Beijing Sihuan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Direct Acting Antivirals Industry Chain Analysis
7.2 Direct Acting Antivirals Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Direct Acting Antivirals Production Mode & Process Analysis
7.4 Direct Acting Antivirals Sales and Marketing
7.4.1 Direct Acting Antivirals Sales Channels
7.4.2 Direct Acting Antivirals Distributors
7.5 Direct Acting Antivirals Customer Analysis
8 Direct Acting Antivirals Market Dynamics
8.1 Direct Acting Antivirals Industry Trends
8.2 Direct Acting Antivirals Market Drivers
8.3 Direct Acting Antivirals Market Challenges
8.4 Direct Acting Antivirals Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Direct Acting Antivirals by Type
1.2.1 Global Direct Acting Antivirals Market Value by Type: 2025 vs 2032
1.2.2 Pangenotypic
1.2.3 Genotype-Specific
1.3 Direct Acting Antivirals by Application
1.3.1 Global Direct Acting Antivirals Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Direct Acting Antivirals Market Size Estimates and Forecasts
1.4.1 Global Direct Acting Antivirals Revenue 2021–2032
1.4.2 Global Direct Acting Antivirals Sales 2021–2032
1.4.3 Global Direct Acting Antivirals Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Direct Acting Antivirals Market Competition by Manufacturers
2.1 Global Direct Acting Antivirals Sales Market Share by Manufacturers (2021–2026)
2.2 Global Direct Acting Antivirals Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Direct Acting Antivirals Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Direct Acting Antivirals, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Direct Acting Antivirals, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Direct Acting Antivirals, Product Types and Applications
2.7 Global Key Manufacturers of Direct Acting Antivirals, Date of Entry into the Industry
2.8 Global Direct Acting Antivirals Market Competitive Situation and Trends
2.8.1 Global Direct Acting Antivirals Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Direct Acting Antivirals Players Market Share by Revenue
2.8.3 Global Direct Acting Antivirals Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Direct Acting Antivirals Market Scenario by Region
3.1 Global Direct Acting Antivirals Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Direct Acting Antivirals Sales by Region: 2021–2032
3.2.1 Global Direct Acting Antivirals Sales by Region: 2021–2026
3.2.2 Global Direct Acting Antivirals Sales by Region: 2027–2032
3.3 Global Direct Acting Antivirals Revenue by Region: 2021–2032
3.3.1 Global Direct Acting Antivirals Revenue by Region: 2021–2026
3.3.2 Global Direct Acting Antivirals Revenue by Region: 2027–2032
3.4 North America Direct Acting Antivirals Market Facts & Figures by Country
3.4.1 North America Direct Acting Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Direct Acting Antivirals Sales by Country (2021–2032)
3.4.3 North America Direct Acting Antivirals Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Direct Acting Antivirals Market Facts & Figures by Country
3.5.1 Europe Direct Acting Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Direct Acting Antivirals Sales by Country (2021–2032)
3.5.3 Europe Direct Acting Antivirals Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Direct Acting Antivirals Market Facts & Figures by Region
3.6.1 Asia Pacific Direct Acting Antivirals Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Direct Acting Antivirals Sales by Region (2021–2032)
3.6.3 Asia Pacific Direct Acting Antivirals Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Direct Acting Antivirals Market Facts & Figures by Country
3.7.1 Latin America Direct Acting Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Direct Acting Antivirals Sales by Country (2021–2032)
3.7.3 Latin America Direct Acting Antivirals Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Direct Acting Antivirals Market Facts & Figures by Country
3.8.1 Middle East and Africa Direct Acting Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Direct Acting Antivirals Sales by Country (2021–2032)
3.8.3 Middle East and Africa Direct Acting Antivirals Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Direct Acting Antivirals Sales by Type (2021–2032)
4.1.1 Global Direct Acting Antivirals Sales by Type (2021–2026)
4.1.2 Global Direct Acting Antivirals Sales by Type (2027–2032)
4.1.3 Global Direct Acting Antivirals Sales Market Share by Type (2021–2032)
4.2 Global Direct Acting Antivirals Revenue by Type (2021–2032)
4.2.1 Global Direct Acting Antivirals Revenue by Type (2021–2026)
4.2.2 Global Direct Acting Antivirals Revenue by Type (2027–2032)
4.2.3 Global Direct Acting Antivirals Revenue Market Share by Type (2021–2032)
4.3 Global Direct Acting Antivirals Price by Type (2021–2032)
5 Segment by Application
5.1 Global Direct Acting Antivirals Sales by Application (2021–2032)
5.1.1 Global Direct Acting Antivirals Sales by Application (2021–2026)
5.1.2 Global Direct Acting Antivirals Sales by Application (2027–2032)
5.1.3 Global Direct Acting Antivirals Sales Market Share by Application (2021–2032)
5.2 Global Direct Acting Antivirals Revenue by Application (2021–2032)
5.2.1 Global Direct Acting Antivirals Revenue by Application (2021–2026)
5.2.2 Global Direct Acting Antivirals Revenue by Application (2027–2032)
5.2.3 Global Direct Acting Antivirals Revenue Market Share by Application (2021–2032)
5.3 Global Direct Acting Antivirals Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences Direct Acting Antivirals Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 Asegua Therapeutics
6.2.1 Asegua Therapeutics Company Information
6.2.2 Asegua Therapeutics Description and Business Overview
6.2.3 Asegua Therapeutics Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Asegua Therapeutics Direct Acting Antivirals Product Portfolio
6.2.5 Asegua Therapeutics Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Merck Direct Acting Antivirals Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Company Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 AbbVie Direct Acting Antivirals Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 Bristol Myers Squibb
6.5.1 Bristol Myers Squibb Company Information
6.5.2 Bristol Myers Squibb Description and Business Overview
6.5.3 Bristol Myers Squibb Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Bristol Myers Squibb Direct Acting Antivirals Product Portfolio
6.5.5 Bristol Myers Squibb Recent Developments/Updates
6.6 Ascletis Pharma
6.6.1 Ascletis Pharma Company Information
6.6.2 Ascletis Pharma Description and Business Overview
6.6.3 Ascletis Pharma Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Ascletis Pharma Direct Acting Antivirals Product Portfolio
6.6.5 Ascletis Pharma Recent Developments/Updates
6.7 Kawin Technology
6.7.1 Kawin Technology Company Information
6.7.2 Kawin Technology Description and Business Overview
6.7.3 Kawin Technology Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Kawin Technology Direct Acting Antivirals Product Portfolio
6.7.5 Kawin Technology Recent Developments/Updates
6.8 YiChang HEC ChangJiang Pharmaceutical
6.8.1 YiChang HEC ChangJiang Pharmaceutical Company Information
6.8.2 YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
6.8.3 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio
6.8.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
6.9 Sanhome Pharmaceutical
6.9.1 Sanhome Pharmaceutical Company Information
6.9.2 Sanhome Pharmaceutical Description and Business Overview
6.9.3 Sanhome Pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio
6.9.5 Sanhome Pharmaceutical Recent Developments/Updates
6.10 Chia Tai Tianqing Pharmaceutical
6.10.1 Chia Tai Tianqing Pharmaceutical Company Information
6.10.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.10.3 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio
6.10.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.11 Cosunter pharmaceutical
6.11.1 Cosunter pharmaceutical Company Information
6.11.2 Cosunter pharmaceutical Description and Business Overview
6.11.3 Cosunter pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio
6.11.5 Cosunter pharmaceutical Recent Developments/Updates
6.12 Beijing Sihuan Pharmaceutical
6.12.1 Beijing Sihuan Pharmaceutical Company Information
6.12.2 Beijing Sihuan Pharmaceutical Description and Business Overview
6.12.3 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio
6.12.5 Beijing Sihuan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Direct Acting Antivirals Industry Chain Analysis
7.2 Direct Acting Antivirals Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Direct Acting Antivirals Production Mode & Process Analysis
7.4 Direct Acting Antivirals Sales and Marketing
7.4.1 Direct Acting Antivirals Sales Channels
7.4.2 Direct Acting Antivirals Distributors
7.5 Direct Acting Antivirals Customer Analysis
8 Direct Acting Antivirals Market Dynamics
8.1 Direct Acting Antivirals Industry Trends
8.2 Direct Acting Antivirals Market Drivers
8.3 Direct Acting Antivirals Market Challenges
8.4 Direct Acting Antivirals Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Direct Acting Antivirals Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Direct Acting Antivirals Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Direct Acting Antivirals Market Competitive Situation by Manufacturers in 2025
Table 4. Global Direct Acting Antivirals Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Direct Acting Antivirals Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Direct Acting Antivirals Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Direct Acting Antivirals Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Direct Acting Antivirals Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Direct Acting Antivirals, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Direct Acting Antivirals, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Direct Acting Antivirals, Product Types and Applications
Table 12. Global Key Manufacturers of Direct Acting Antivirals, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Direct Acting Antivirals Companies by Tier (Tier 1, Tier 2, Tier 3), based on Direct Acting Antivirals Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Direct Acting Antivirals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Direct Acting Antivirals Sales by Region (K Units), 2021–2026
Table 18. Global Direct Acting Antivirals Sales Market Share by Region (2021–2026)
Table 19. Global Direct Acting Antivirals Sales by Region (K Units), 2027–2032
Table 20. Global Direct Acting Antivirals Sales Market Share by Region (2027–2032)
Table 21. Global Direct Acting Antivirals Revenue by Region (US$ Million), 2021–2026
Table 22. Global Direct Acting Antivirals Revenue Market Share by Region (2021–2026)
Table 23. Global Direct Acting Antivirals Revenue by Region (US$ Million), 2027–2032
Table 24. Global Direct Acting Antivirals Revenue Market Share by Region (2027–2032)
Table 25. North America Direct Acting Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Direct Acting Antivirals Sales by Country (K Units), 2021–2026
Table 27. North America Direct Acting Antivirals Sales by Country (K Units), 2027–2032
Table 28. North America Direct Acting Antivirals Revenue by Country (US$ Million), 2021–2026
Table 29. North America Direct Acting Antivirals Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Direct Acting Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Direct Acting Antivirals Sales by Country (K Units), 2021–2026
Table 32. Europe Direct Acting Antivirals Sales by Country (K Units), 2027–2032
Table 33. Europe Direct Acting Antivirals Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Direct Acting Antivirals Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Direct Acting Antivirals Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Direct Acting Antivirals Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Direct Acting Antivirals Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Direct Acting Antivirals Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Direct Acting Antivirals Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Direct Acting Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Direct Acting Antivirals Sales by Country (K Units), 2021–2026
Table 42. Latin America Direct Acting Antivirals Sales by Country (K Units), 2027–2032
Table 43. Latin America Direct Acting Antivirals Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Direct Acting Antivirals Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Direct Acting Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Direct Acting Antivirals Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Direct Acting Antivirals Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Direct Acting Antivirals Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Direct Acting Antivirals Revenue by Country (US$ Million), 2027–2032
Table 50. Global Direct Acting Antivirals Sales (K Units) by Type (2021–2026)
Table 51. Global Direct Acting Antivirals Sales (K Units) by Type (2027–2032)
Table 52. Global Direct Acting Antivirals Sales Market Share by Type (2021–2026)
Table 53. Global Direct Acting Antivirals Sales Market Share by Type (2027–2032)
Table 54. Global Direct Acting Antivirals Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Direct Acting Antivirals Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Direct Acting Antivirals Revenue Market Share by Type (2021–2026)
Table 57. Global Direct Acting Antivirals Revenue Market Share by Type (2027–2032)
Table 58. Global Direct Acting Antivirals Price (US$/Unit) by Type (2021–2026)
Table 59. Global Direct Acting Antivirals Price (US$/Unit) by Type (2027–2032)
Table 60. Global Direct Acting Antivirals Sales (K Units) by Application (2021–2026)
Table 61. Global Direct Acting Antivirals Sales (K Units) by Application (2027–2032)
Table 62. Global Direct Acting Antivirals Sales Market Share by Application (2021–2026)
Table 63. Global Direct Acting Antivirals Sales Market Share by Application (2027–2032)
Table 64. Global Direct Acting Antivirals Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Direct Acting Antivirals Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Direct Acting Antivirals Revenue Market Share by Application (2021–2026)
Table 67. Global Direct Acting Antivirals Revenue Market Share by Application (2027–2032)
Table 68. Global Direct Acting Antivirals Price (US$/Unit) by Application (2021–2026)
Table 69. Global Direct Acting Antivirals Price (US$/Unit) by Application (2027–2032)
Table 70. Gilead Sciences Company Information
Table 71. Gilead Sciences Description and Business Overview
Table 72. Gilead Sciences Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Gilead Sciences Direct Acting Antivirals Product
Table 74. Gilead Sciences Recent Developments/Updates
Table 75. Asegua Therapeutics Company Information
Table 76. Asegua Therapeutics Description and Business Overview
Table 77. Asegua Therapeutics Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Asegua Therapeutics Direct Acting Antivirals Product
Table 79. Asegua Therapeutics Recent Developments/Updates
Table 80. Merck Company Information
Table 81. Merck Description and Business Overview
Table 82. Merck Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Merck Direct Acting Antivirals Product
Table 84. Merck Recent Developments/Updates
Table 85. AbbVie Company Information
Table 86. AbbVie Description and Business Overview
Table 87. AbbVie Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. AbbVie Direct Acting Antivirals Product
Table 89. AbbVie Recent Developments/Updates
Table 90. Bristol Myers Squibb Company Information
Table 91. Bristol Myers Squibb Description and Business Overview
Table 92. Bristol Myers Squibb Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Bristol Myers Squibb Direct Acting Antivirals Product
Table 94. Bristol Myers Squibb Recent Developments/Updates
Table 95. Ascletis Pharma Company Information
Table 96. Ascletis Pharma Description and Business Overview
Table 97. Ascletis Pharma Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Ascletis Pharma Direct Acting Antivirals Product
Table 99. Ascletis Pharma Recent Developments/Updates
Table 100. Kawin Technology Company Information
Table 101. Kawin Technology Description and Business Overview
Table 102. Kawin Technology Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Kawin Technology Direct Acting Antivirals Product
Table 104. Kawin Technology Recent Developments/Updates
Table 105. YiChang HEC ChangJiang Pharmaceutical Company Information
Table 106. YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
Table 107. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product
Table 109. YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
Table 110. Sanhome Pharmaceutical Company Information
Table 111. Sanhome Pharmaceutical Description and Business Overview
Table 112. Sanhome Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Sanhome Pharmaceutical Direct Acting Antivirals Product
Table 114. Sanhome Pharmaceutical Recent Developments/Updates
Table 115. Chia Tai Tianqing Pharmaceutical Company Information
Table 116. Chia Tai Tianqing Pharmaceutical Description and Business Overview
Table 117. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product
Table 119. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 120. Cosunter pharmaceutical Company Information
Table 121. Cosunter pharmaceutical Description and Business Overview
Table 122. Cosunter pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Cosunter pharmaceutical Direct Acting Antivirals Product
Table 124. Cosunter pharmaceutical Recent Developments/Updates
Table 125. Beijing Sihuan Pharmaceutical Company Information
Table 126. Beijing Sihuan Pharmaceutical Description and Business Overview
Table 127. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product
Table 129. Beijing Sihuan Pharmaceutical Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Direct Acting Antivirals Distributors List
Table 133. Direct Acting Antivirals Customers List
Table 134. Direct Acting Antivirals Market Trends
Table 135. Direct Acting Antivirals Market Drivers
Table 136. Direct Acting Antivirals Market Challenges
Table 137. Direct Acting Antivirals Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Direct Acting Antivirals
Figure 2. Global Direct Acting Antivirals Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Direct Acting Antivirals Market Share by Type: 2025 & 2032
Figure 4. Pangenotypic Product Picture
Figure 5. Genotype-Specific Product Picture
Figure 6. Global Direct Acting Antivirals Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Direct Acting Antivirals Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Direct Acting Antivirals Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Direct Acting Antivirals Market Size (US$ Million), 2021–2032
Figure 13. Global Direct Acting Antivirals Sales (K Units), 2021–2032
Figure 14. Global Direct Acting Antivirals Average Price (US$/Unit), 2021–2032
Figure 15. Direct Acting Antivirals Report Years Considered
Figure 16. Direct Acting Antivirals Sales Share by Manufacturers in 2025
Figure 17. Global Direct Acting Antivirals Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Direct Acting Antivirals Players: Market Share by Revenue in Direct Acting Antivirals in 2025
Figure 19. Direct Acting Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Direct Acting Antivirals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Direct Acting Antivirals Sales Market Share by Country (2021–2032)
Figure 22. North America Direct Acting Antivirals Revenue Market Share by Country (2021–2032)
Figure 23. United States Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Direct Acting Antivirals Sales Market Share by Country (2021–2032)
Figure 26. Europe Direct Acting Antivirals Revenue Market Share by Country (2021–2032)
Figure 27. Germany Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Direct Acting Antivirals Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Direct Acting Antivirals Revenue Market Share by Region (2021–2032)
Figure 34. China Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Direct Acting Antivirals Sales Market Share by Country (2021–2032)
Figure 42. Latin America Direct Acting Antivirals Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Direct Acting Antivirals Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Direct Acting Antivirals Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Direct Acting Antivirals by Type (2021–2032)
Figure 53. Global Revenue Market Share of Direct Acting Antivirals by Type (2021–2032)
Figure 54. Global Direct Acting Antivirals Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Direct Acting Antivirals by Application (2021–2032)
Figure 56. Global Revenue Market Share of Direct Acting Antivirals by Application (2021–2032)
Figure 57. Global Direct Acting Antivirals Price (US$/Unit) by Application (2021–2032)
Figure 58. Direct Acting Antivirals Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Direct Acting Antivirals Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Direct Acting Antivirals Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Direct Acting Antivirals Market Competitive Situation by Manufacturers in 2025
Table 4. Global Direct Acting Antivirals Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Direct Acting Antivirals Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Direct Acting Antivirals Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Direct Acting Antivirals Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Direct Acting Antivirals Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Direct Acting Antivirals, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Direct Acting Antivirals, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Direct Acting Antivirals, Product Types and Applications
Table 12. Global Key Manufacturers of Direct Acting Antivirals, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Direct Acting Antivirals Companies by Tier (Tier 1, Tier 2, Tier 3), based on Direct Acting Antivirals Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Direct Acting Antivirals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Direct Acting Antivirals Sales by Region (K Units), 2021–2026
Table 18. Global Direct Acting Antivirals Sales Market Share by Region (2021–2026)
Table 19. Global Direct Acting Antivirals Sales by Region (K Units), 2027–2032
Table 20. Global Direct Acting Antivirals Sales Market Share by Region (2027–2032)
Table 21. Global Direct Acting Antivirals Revenue by Region (US$ Million), 2021–2026
Table 22. Global Direct Acting Antivirals Revenue Market Share by Region (2021–2026)
Table 23. Global Direct Acting Antivirals Revenue by Region (US$ Million), 2027–2032
Table 24. Global Direct Acting Antivirals Revenue Market Share by Region (2027–2032)
Table 25. North America Direct Acting Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Direct Acting Antivirals Sales by Country (K Units), 2021–2026
Table 27. North America Direct Acting Antivirals Sales by Country (K Units), 2027–2032
Table 28. North America Direct Acting Antivirals Revenue by Country (US$ Million), 2021–2026
Table 29. North America Direct Acting Antivirals Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Direct Acting Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Direct Acting Antivirals Sales by Country (K Units), 2021–2026
Table 32. Europe Direct Acting Antivirals Sales by Country (K Units), 2027–2032
Table 33. Europe Direct Acting Antivirals Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Direct Acting Antivirals Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Direct Acting Antivirals Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Direct Acting Antivirals Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Direct Acting Antivirals Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Direct Acting Antivirals Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Direct Acting Antivirals Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Direct Acting Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Direct Acting Antivirals Sales by Country (K Units), 2021–2026
Table 42. Latin America Direct Acting Antivirals Sales by Country (K Units), 2027–2032
Table 43. Latin America Direct Acting Antivirals Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Direct Acting Antivirals Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Direct Acting Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Direct Acting Antivirals Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Direct Acting Antivirals Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Direct Acting Antivirals Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Direct Acting Antivirals Revenue by Country (US$ Million), 2027–2032
Table 50. Global Direct Acting Antivirals Sales (K Units) by Type (2021–2026)
Table 51. Global Direct Acting Antivirals Sales (K Units) by Type (2027–2032)
Table 52. Global Direct Acting Antivirals Sales Market Share by Type (2021–2026)
Table 53. Global Direct Acting Antivirals Sales Market Share by Type (2027–2032)
Table 54. Global Direct Acting Antivirals Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Direct Acting Antivirals Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Direct Acting Antivirals Revenue Market Share by Type (2021–2026)
Table 57. Global Direct Acting Antivirals Revenue Market Share by Type (2027–2032)
Table 58. Global Direct Acting Antivirals Price (US$/Unit) by Type (2021–2026)
Table 59. Global Direct Acting Antivirals Price (US$/Unit) by Type (2027–2032)
Table 60. Global Direct Acting Antivirals Sales (K Units) by Application (2021–2026)
Table 61. Global Direct Acting Antivirals Sales (K Units) by Application (2027–2032)
Table 62. Global Direct Acting Antivirals Sales Market Share by Application (2021–2026)
Table 63. Global Direct Acting Antivirals Sales Market Share by Application (2027–2032)
Table 64. Global Direct Acting Antivirals Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Direct Acting Antivirals Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Direct Acting Antivirals Revenue Market Share by Application (2021–2026)
Table 67. Global Direct Acting Antivirals Revenue Market Share by Application (2027–2032)
Table 68. Global Direct Acting Antivirals Price (US$/Unit) by Application (2021–2026)
Table 69. Global Direct Acting Antivirals Price (US$/Unit) by Application (2027–2032)
Table 70. Gilead Sciences Company Information
Table 71. Gilead Sciences Description and Business Overview
Table 72. Gilead Sciences Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Gilead Sciences Direct Acting Antivirals Product
Table 74. Gilead Sciences Recent Developments/Updates
Table 75. Asegua Therapeutics Company Information
Table 76. Asegua Therapeutics Description and Business Overview
Table 77. Asegua Therapeutics Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Asegua Therapeutics Direct Acting Antivirals Product
Table 79. Asegua Therapeutics Recent Developments/Updates
Table 80. Merck Company Information
Table 81. Merck Description and Business Overview
Table 82. Merck Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Merck Direct Acting Antivirals Product
Table 84. Merck Recent Developments/Updates
Table 85. AbbVie Company Information
Table 86. AbbVie Description and Business Overview
Table 87. AbbVie Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. AbbVie Direct Acting Antivirals Product
Table 89. AbbVie Recent Developments/Updates
Table 90. Bristol Myers Squibb Company Information
Table 91. Bristol Myers Squibb Description and Business Overview
Table 92. Bristol Myers Squibb Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Bristol Myers Squibb Direct Acting Antivirals Product
Table 94. Bristol Myers Squibb Recent Developments/Updates
Table 95. Ascletis Pharma Company Information
Table 96. Ascletis Pharma Description and Business Overview
Table 97. Ascletis Pharma Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Ascletis Pharma Direct Acting Antivirals Product
Table 99. Ascletis Pharma Recent Developments/Updates
Table 100. Kawin Technology Company Information
Table 101. Kawin Technology Description and Business Overview
Table 102. Kawin Technology Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Kawin Technology Direct Acting Antivirals Product
Table 104. Kawin Technology Recent Developments/Updates
Table 105. YiChang HEC ChangJiang Pharmaceutical Company Information
Table 106. YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
Table 107. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product
Table 109. YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
Table 110. Sanhome Pharmaceutical Company Information
Table 111. Sanhome Pharmaceutical Description and Business Overview
Table 112. Sanhome Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Sanhome Pharmaceutical Direct Acting Antivirals Product
Table 114. Sanhome Pharmaceutical Recent Developments/Updates
Table 115. Chia Tai Tianqing Pharmaceutical Company Information
Table 116. Chia Tai Tianqing Pharmaceutical Description and Business Overview
Table 117. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product
Table 119. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 120. Cosunter pharmaceutical Company Information
Table 121. Cosunter pharmaceutical Description and Business Overview
Table 122. Cosunter pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Cosunter pharmaceutical Direct Acting Antivirals Product
Table 124. Cosunter pharmaceutical Recent Developments/Updates
Table 125. Beijing Sihuan Pharmaceutical Company Information
Table 126. Beijing Sihuan Pharmaceutical Description and Business Overview
Table 127. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product
Table 129. Beijing Sihuan Pharmaceutical Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Direct Acting Antivirals Distributors List
Table 133. Direct Acting Antivirals Customers List
Table 134. Direct Acting Antivirals Market Trends
Table 135. Direct Acting Antivirals Market Drivers
Table 136. Direct Acting Antivirals Market Challenges
Table 137. Direct Acting Antivirals Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Direct Acting Antivirals
Figure 2. Global Direct Acting Antivirals Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Direct Acting Antivirals Market Share by Type: 2025 & 2032
Figure 4. Pangenotypic Product Picture
Figure 5. Genotype-Specific Product Picture
Figure 6. Global Direct Acting Antivirals Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Direct Acting Antivirals Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Direct Acting Antivirals Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Direct Acting Antivirals Market Size (US$ Million), 2021–2032
Figure 13. Global Direct Acting Antivirals Sales (K Units), 2021–2032
Figure 14. Global Direct Acting Antivirals Average Price (US$/Unit), 2021–2032
Figure 15. Direct Acting Antivirals Report Years Considered
Figure 16. Direct Acting Antivirals Sales Share by Manufacturers in 2025
Figure 17. Global Direct Acting Antivirals Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Direct Acting Antivirals Players: Market Share by Revenue in Direct Acting Antivirals in 2025
Figure 19. Direct Acting Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Direct Acting Antivirals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Direct Acting Antivirals Sales Market Share by Country (2021–2032)
Figure 22. North America Direct Acting Antivirals Revenue Market Share by Country (2021–2032)
Figure 23. United States Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Direct Acting Antivirals Sales Market Share by Country (2021–2032)
Figure 26. Europe Direct Acting Antivirals Revenue Market Share by Country (2021–2032)
Figure 27. Germany Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Direct Acting Antivirals Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Direct Acting Antivirals Revenue Market Share by Region (2021–2032)
Figure 34. China Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Direct Acting Antivirals Sales Market Share by Country (2021–2032)
Figure 42. Latin America Direct Acting Antivirals Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Direct Acting Antivirals Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Direct Acting Antivirals Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Direct Acting Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Direct Acting Antivirals by Type (2021–2032)
Figure 53. Global Revenue Market Share of Direct Acting Antivirals by Type (2021–2032)
Figure 54. Global Direct Acting Antivirals Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Direct Acting Antivirals by Application (2021–2032)
Figure 56. Global Revenue Market Share of Direct Acting Antivirals by Application (2021–2032)
Figure 57. Global Direct Acting Antivirals Price (US$/Unit) by Application (2021–2032)
Figure 58. Direct Acting Antivirals Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232